CompletedEarly Phase 1NCT04000165

A Dose-Finding Study of AG-348 in Sickle Cell Disease

Studying Sickle cell disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institutes of Health Clinical Center (CC)
Principal Investigator
Swee Lay Thein, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Intervention
AG-348(drug)
Enrollment
17 enrolled
Eligibility
18-70 years · All sexes
Timeline
2019 – 2021

Study locations (1)

Collaborators

National Heart, Lung, and Blood Institute (NHLBI) · Agios Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04000165 on ClinicalTrials.gov

Other trials for Sickle cell disease

Additional recruiting or active studies for the same condition.

See all trials for Sickle cell disease →

← Back to all trials